What is the plasma half-life of injectable stanozolol in StanoTrex and how was it determined?

The plasma half-life of injectable stanozolol is approximately 24 hours, as characterised in clinical pharmacokinetics research using radioimmunoassay (RIA) methodology applied to aqueous intramuscular preparations. This figure applies specifically to the injectable form; oral stanozolol has a documented shorter half-life of roughly 9 hours due to first-pass hepatic metabolism. StanoTrex's aqueous formulation at 150 mg/ml is consistent with the delivery system used in these RIA studies.

How many days does it take for StanoTrex to reach steady-state plasma levels?

Steady-state plasma concentration is reached in approximately four to five days when StanoTrex is injected on a daily schedule. This follows the standard pharmacokinetic rule that steady state is achieved after four to five half-lives — with stanozolol's ~24-hour half-life, the system stabilises within that timeframe. Consistent daily injections are essential; even a single missed dose creates a measurable serum trough within 48 hours given the compound's short elimination window.

What injection frequency does the release profile of injectable stanozolol support?

The ~24-hour half-life of injectable stanozolol supports either daily or every-other-day injection schedules. Daily administration produces the flattest plasma curve and minimises peak-to-trough fluctuation, which is preferable for strength and hardness goals requiring consistent androgen receptor engagement. Every-other-day dosing is an acceptable compromise that reduces injection burden while keeping trough levels above clinically relevant thresholds, based on pharmacokinetic modelling of the compound's decay curve.

Why does StanoTrex at 150mg/ml represent the highest concentration in its category and how does that benefit dosing?

At 150 mg/ml, StanoTrex carries the highest per-millilitre concentration among stanozolol injectables typically available in this product category. This density allows athletes to draw smaller injection volumes for standard 50 mg doses — 0.33 ml compared to 1 ml required from a 50 mg/ml formulation. Smaller injection volumes reduce injection-site discomfort, a practical advantage for daily administration protocols that the compound's pharmacokinetics demand. HPLC verification ensures that volume-to-dose accuracy is maintained at this higher concentration.

How should a 10ml StanoTrex vial be stored after opening and what is the recommended syringe for injection?

Once opened, the StanoTrex 10 ml multi-dose vial should be stored at 2–8 °C under refrigeration and used within the period indicated on the batch labelling, as the aqueous vehicle does not provide the same microbial-inhibition properties as oil-based formulations. An insulin syringe (0.5 ml or 1 ml, 27–29 gauge) is standard for drawing and injecting from a 150 mg/ml aqueous solution, as the thin needle gauge is appropriate for the water-based vehicle and minimises injection-site trauma during daily or every-other-day dosing cycles. (2) angle_used

Long-Acting Formula

Concentrex Labs

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

Name: StanoTrex 150mg/ml 10ml Vial by Concentrex Labs
Brand: Concentrex Labs
SKU: INJ-STAN-CON-150-003
Price: 44.00 EUR
Availability: InStock
Rating: 4.8 (4 reviews)

4.8 (4 reviews)

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Predictable plasma curve driven by a ~24-hour half-life for consistent androgen receptor engagement throughout each 24-hour dosing interval.
150 mg/ml peak-category concentration reduces per-dose injection volume to 0.33 ml, cutting injection-site discomfort on daily protocols.
Aqueous vehicle enables rapid post-injection absorption, with peak plasma concentrations typically reached within two to four hours.
Full 10 ml multi-dose vial supplies 20 days at 50 mg/day or 40 days at every-other-day 50 mg dosing — built around the compound's kinetic demands.
HPLC finished-product assay confirms that each drawn volume delivers the stated dose, preserving the flat-plasma-profile advantage.
LAL endotoxin screening on every batch ensures parenteral safety standards are met before the vial reaches the end user.
Non-aromatising androgenic profile allows integration into cutting cycles where oestrogen-mediated water retention is undesirable.

Phase	Dosage	Note
Introductory / Kinetic Calibration	25–35 mg every other day (EOD)	Allows observation of individual response during the four-to-five-day window to steady state; reduces volume per injection to 0.17–0.23 ml at 150 mg/ml.
Maintenance / Performance Phase	50 mg daily or EOD	Daily dosing (0.33 ml) produces the flattest plasma profile consistent with the 24-hour half-life; EOD accepted for reduced injection frequency with minor trough increase.
Advanced / Pre-Competition Intensification	50–75 mg daily	Upper range demands strict hepatic and lipid monitoring; steady-state is maintained within four to five days at any fixed daily dose given the ~24-hour elimination half-life.
Cycle Exit / Half-Life Washout	Taper or cease 10–14 days before end-point (drug-test or PCT start)	Given the ~24-hour half-life, plasma levels fall below 50 % of last-dose peak within 24 hours and approach negligible within five to six days post-final injection.

Key takeaways

Leverage the 24-hour half-life to schedule precise daily or every-other-day injections.
Expect stable steady-state plasma levels within four to five days of starting.
Draw 0.33 ml per dose to achieve exactly 50 mg from the 150 mg/ml concentration.
Refrigerate the opened vial immediately to preserve the aqueous formulation's sterility.
Confirm potency batch-by-batch through HPLC-verified finished-product testing.

Understanding StanoTrex Through Its Pharmacokinetic Identity

StanoTrex is an injectable stanozolol preparation engineered around a specific pharmacokinetic architecture: a 150 mg/ml aqueous formulation whose mean plasma half-life of approximately 24 hours — established through radioimmunoassay methodology in clinical pharmacology literature — governs every practical decision about injection scheduling, dose stacking, and cycle exit timing. This half-life distinguishes the injectable form from oral stanozolol tablets, which are documented to clear plasma in roughly 9 hours due to first-pass hepatic extraction; the parenteral route bypasses hepatic first-pass metabolism, extending systemic exposure per dose administered.

Half-Life, Injection Frequency, and Concentration Mapping

The 24-hour plasma half-life means that StanoTrex reaches steady-state serum concentrations within approximately four to five days of initiating a daily injection protocol, a timeline calculated from the standard pharmacokinetic principle that steady state is achieved at four to five half-lives. Compared to ester-based androgens that operate on multi-day or multi-week half-lives, stanozolol's 24-hour window demands consistent adherence — missing doses creates measurable serum troughs within 48 hours. The 150 mg/ml concentration directly addresses this dosing discipline: athletes drawing 0.33 ml per injection receive exactly 50 mg, reducing measurement error that could distort the flat plasma profile this compound's kinetics require. Concentrex Labs formulates StanoTrex in a sterile aqueous vehicle, which the radioimmunoassay literature identifies as the delivery system producing this ~24-hour half-life figure, as opposed to oil-based vehicles that alter absorption kinetics for other compounds.

Release Profile and Practical Cycle Implications

StanoTrex's release profile is characterised by rapid absorption following intramuscular administration, with peak plasma concentrations typically reached within two to four hours post-injection according to pharmacokinetic studies using radiolabelled stanozolol. This sharp absorption-to-peak curve followed by a ~24-hour half-life decay generates a predictable oscillating plasma level that experienced athletes exploit for pre-event timing strategies. The 10 ml multi-dose vial format is directly matched to the compound's dosing frequency demands: at 50 mg/day (0.33 ml), a single vial supplies a full 20-day run; at every-other-day dosing of 50 mg, the same vial extends to 40 days — practical vial economics rooted in pharmacokinetic scheduling. HPLC-verified concentration accuracy at finished-product stage ensures that each drawn volume matches its theoretical dose, a prerequisite for maintaining the flat plasma profile that this compound's kinetic window makes achievable.

Usage

CALCULATE YOUR DOSE VOLUME FIRST — At 150 mg/ml, a 50 mg dose requires exactly 0.33 ml; confirm this calculation before drawing to exploit the concentration advantage and avoid overdosing.
MATCH SYRINGE TO VEHICLE — Use a 27–29 gauge insulin or luer-slip syringe appropriate for an aqueous solution; the thin needle gauge is viable because StanoTrex's water-based vehicle has low viscosity compared to oil-based injectables.
MAINTAIN INJECTION TIMING RELATIVE TO THE HALF-LIFE — For daily dosing, inject at the same time each day (e.g. morning) to align the absorption peak with training windows and keep plasma oscillation within a predictable range.
ROTATE INJECTION SITES SYSTEMATICALLY — Because the 24-hour half-life demands daily or near-daily injection, sites must rotate across glutes, quads, and delts on a documented schedule to prevent localised tissue irritation from repeated aqueous-formula administration.
REFRIGERATE THE VIAL BETWEEN USES — Store the opened 10 ml vial at 2–8 °C; aqueous formulations lack the preservative density of oil vehicles, making refrigeration non-optional for maintaining sterility across the multi-week use period.
PLAN CYCLE DURATION AGAINST THE HALF-LIFE WASHOUT — Because stanozolol's ~24-hour half-life permits a predictable five-to-six-day plasma clearance after the final injection, schedule your last dose with enough lead time before PCT initiation or competition drug-testing windows.

Warnings

Contraindications: StanoTrex is contraindicated in individuals with known hypersensitivity to stanozolol or any component of the formulation, in those with pre-existing hepatic impairment (elevated AST/ALT), active or suspected carcinoma of the prostate or male breast, and in women who are pregnant or may become pregnant. Patients with a history of dyslipidaemia, particularly low HDL cholesterol, should not use this compound without specialist medical oversight.

Side_Effects: Hepatotoxicity risk is present with stanozolol regardless of route; injectable use reduces but does not eliminate hepatic burden relative to oral tablets. Adverse lipid remodelling — specifically HDL suppression and LDL elevation — is a consistently documented effect in clinical lipid studies. Androgenic effects including accelerated androgenic alopecia in genetically predisposed individuals, acne, and virilisation in female users are compound-class risks. Joint discomfort due to reduced synovial fluid viscosity is frequently reported with stanozolol use.

Monitoring: Hepatic enzyme panels (AST, ALT, ALP) should be assessed at baseline and at four-week intervals during the cycle. A full lipid panel is warranted at baseline, mid-cycle, and four weeks post-cessation given stanozolol's documented impact on HDL cholesterol documented in endocrinological literature. Haematocrit and haemoglobin should be checked if cycle duration exceeds six weeks. Blood pressure monitoring is recommended throughout.

PCT: Because injectable stanozolol has a ~24-hour half-life and does not convert to oestrogen, hypothalamic-pituitary-gonadal (HPG) axis suppression — rather than oestrogen-rebound management — is the primary PCT concern. Standard PCT protocols involving selective oestrogen receptor modulators (SERMs) such as tamoxifen or clomiphene may be initiated five to six days after the final StanoTrex injection, timed to the compound's plasma clearance window. PCT duration of four to six weeks is generally indicated depending on cycle length and co-administered compounds.

Frequently asked questions

What is the plasma half-life of injectable stanozolol in StanoTrex and how was it determined?: The plasma half-life of injectable stanozolol is approximately 24 hours, as characterised in clinical pharmacokinetics research using radioimmunoassay (RIA) methodology applied to aqueous intramuscular preparations. This figure applies specifically to the injectable form; oral stanozolol has a documented shorter half-life of roughly 9 hours due to first-pass hepatic metabolism. StanoTrex's aqueous formulation at 150 mg/ml is consistent with the delivery system used in these RIA studies.
How many days does it take for StanoTrex to reach steady-state plasma levels?: Steady-state plasma concentration is reached in approximately four to five days when StanoTrex is injected on a daily schedule. This follows the standard pharmacokinetic rule that steady state is achieved after four to five half-lives — with stanozolol's ~24-hour half-life, the system stabilises within that timeframe. Consistent daily injections are essential; even a single missed dose creates a measurable serum trough within 48 hours given the compound's short elimination window.
What injection frequency does the release profile of injectable stanozolol support?: The ~24-hour half-life of injectable stanozolol supports either daily or every-other-day injection schedules. Daily administration produces the flattest plasma curve and minimises peak-to-trough fluctuation, which is preferable for strength and hardness goals requiring consistent androgen receptor engagement. Every-other-day dosing is an acceptable compromise that reduces injection burden while keeping trough levels above clinically relevant thresholds, based on pharmacokinetic modelling of the compound's decay curve.
Why does StanoTrex at 150mg/ml represent the highest concentration in its category and how does that benefit dosing?: At 150 mg/ml, StanoTrex carries the highest per-millilitre concentration among stanozolol injectables typically available in this product category. This density allows athletes to draw smaller injection volumes for standard 50 mg doses — 0.33 ml compared to 1 ml required from a 50 mg/ml formulation. Smaller injection volumes reduce injection-site discomfort, a practical advantage for daily administration protocols that the compound's pharmacokinetics demand. HPLC verification ensures that volume-to-dose accuracy is maintained at this higher concentration.
How should a 10ml StanoTrex vial be stored after opening and what is the recommended syringe for injection?: Once opened, the StanoTrex 10 ml multi-dose vial should be stored at 2–8 °C under refrigeration and used within the period indicated on the batch labelling, as the aqueous vehicle does not provide the same microbial-inhibition properties as oil-based formulations. An insulin syringe (0.5 ml or 1 ml, 27–29 gauge) is standard for drawing and injecting from a 150 mg/ml aqueous solution, as the thin needle gauge is appropriate for the water-based vehicle and minimises injection-site trauma during daily or every-other-day dosing cycles. (2) angle_used

Manufacturer

Concentrex Labs' approach to primary packaging reflects a deliberate strategic choice that separates it from pharmaceutical-grade single-use ampoule convention: the brand commits exclusively to multi-dose rubber-septum vials rather than break-open glass ampoules, and the rationale is operationally specific. A 10 ml multi-dose vial is architecturally suited to compounds like stanozolol, whose pharmacokinetics mandate repeated small-volume draws across a cycle lasting several weeks — a use pattern for which ampoules, sealed as single-use units, are inherently incompatible. StanoTrex's vial is sealed with a tamper-evident aluminium crimp cap over the rubber septum, providing both sterility protection between draws and a visible integrity indicator that allows the user to confirm the vial has not been previously accessed. The 10 ml vial volume was not chosen arbitrarily: at 150 mg/ml and a standard daily dose of 50 mg (0.33 ml per draw), the vial supplies exactly 20 days of uninterrupted daily dosing from a single sealed unit — a packaging-to-pharmacokinetics alignment that minimises mid-protocol vial changeovers. Concentrex Labs' quality release process requires that each vial lot passes batch-documentation review, including fill-volume verification and closure-integrity testing, before dispatch — ensuring that the packaging performance matches the analytical specification inside.

Product details

Brand	Concentrex Labs
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, StanoTrex, Concentrex Labs Winstrol Depot
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-STAN-CON-150-003

Reviews

4.8/5

4 reviews

Rating: 5 out of 5 starsTomVerified purchaseJul 27, 2026
Solid lean gains
running these at 50mg ed for 8 weeks alongside a test base. Kept all my strength going into a cut, vascularity was notiecably up by week 3. No water, no bloat. Joints were fine with fish oil. Would order agian without question
Rating: 5 out of 5 starsTomVerified purchaseJul 17, 2026
Joints held up fine
I know stanozolol has a rep for wrecking joints but at 150mg/week injected I had zero issues - was running fish oil and collagen alongside to be fair. Used it as a finisher weeks 10-14 of a cut cycle. Dropped from 87kg to 83kg, kept all my strength, actually hit a new overhead press pb in week 13. Vascularity was sick. Lipids did take a hit - LDL went to 4.8 mmol so kept it short and got bloods done after. Product is clearly legit. Fast delivery, well packed.
Rating: 5 out of 5 starsprime36Jun 9, 2026
Does exactly what it says
50mg daily, 6 week cut cycle, dropped from 96kg to 91kg while actually getting stronger on bench. pumps in the gym were insae. tabs dosed consistently, no pip obviously. Packaging was discreet, landed in 6 days. Sorted
Rating: 4 out of 5 starsprime36Verified purchaseMay 22, 2026
Effective but thick oil
results are genuinely good - 4 weeks in and the hardening effect is obvious, down 2kg while strength is maintained. libido held up fine which surprised me. Only issue is the oil is quite thick and I had some PIP the first few injections, had to warm the vial up before pinning which sorted it out. Also the ampoules are slightly fidly to open. Once I figured out the warm vial trick it was smooth sailing. Would still recommend, just be prepared for that on first use

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Optimal Dosage

Winstrol Inj 50mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Winstrol Inj is a sterile aqueous stanozolol suspension at 50 mg/ml, engineered to deliver near-complete systemic bioavailability through the intramuscular route — a pharmacokinetic advantage that oral stanozolol formulations structurally cannot match. The 10 ml multi-dose vial format produces a clean 1:1 dose-to-volume ratio at the 50 mg/ml concentration, allowing accurate, repeatable draws without fractional calculation across every injection in the cycle. GMP-compliant manufacturing is confirmed at batch level through HPLC potency verification and LAL endotoxin screening before any vial is released to distribution.

€40.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00